

SEATTLE GENETICS INC /WA  
Form 8-K  
September 09, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 9, 2015**

**Seattle Genetics, Inc.**

**(Exact name of Registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction of  
incorporation or organization)**

**0-32405**  
**(Commission**  
**File Number)**  
**21823 30<sup>th</sup> Drive SE**

**91-1874389**  
**(I.R.S. Employer**  
**Identification No.)**

**Bothell, Washington 98021**

Edgar Filing: SEATTLE GENETICS INC /WA - Form 8-K

**(Address of principal executive offices, including zip code)**

**(425) 527-4000**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, Seattle Genetics, the Company, we, us and our refer to Seattle Genetics, Inc., a Delaware corporation and its subsidiaries on a consolidated basis.

**Item 8.01 Other Events.**

*Updated Company Disclosure*

On September 9, 2015, we filed with the SEC a preliminary prospectus supplement pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the Preliminary Prospectus Supplement ), relating to a proposed public offering of shares of our common stock (the Public Offering ). The Preliminary Prospectus Supplement for the Public Offering contains updated Company risk factor disclosure as well as an updated description of certain aspects of our business. Accordingly, we are filing information for the purpose of supplementing and updating the risk factor disclosure contained in our prior public filings, including those discussed under the heading Item 1A. Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed with the SEC on July 30, 2015. We are also updating certain aspects of the description of our business from that described under the heading, Item 1. Business in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on February 27, 2015. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

| Exhibit No. | Description                |
|-------------|----------------------------|
| 99.1        | Updated Company Disclosure |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SEATTLE GENETICS, INC.**

Dated: September 9, 2015

/s/ CLAY B. SIEGALL

By:

Clay B. Siegall

*President and Chief Executive Officer*

**EXHIBIT INDEX**

| Exhibit No. | Description                |
|-------------|----------------------------|
| 99.1        | Updated Company Disclosure |